Alireza Kamali; Masoumeh Sofian; Behnam Mahmodiyeh; Shamim Valibeik; Elham Farahani
Abstract
Background: Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) has been associated with severe respiratory disease incidence and ...
Read More
Background: Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) has been associated with severe respiratory disease incidence and increased morbidity and mortality of patients all over the world. The aim of this study is evaluation of Atorvastatin effect on patients with COVID-19.Materials and methods: This is a prospective randomized controlled trial with 100 adults diagnosed with COVID-19. Participants randomly received Atorvastatin or just routine protocol of treatment for 10 days. Primary outcomes are duration of fever and cough, atrial oxygen saturation (SPO2), length of hospitalization and ICU stay, duration of oxygen therapy or intubation, and mortality rate. Secondary outcomes contain white blood cell count, lymphocyte percentage, lactate dehydrogenase, and creatine phosphokinase level.Results: There was no significant difference in age and sex between two groups. Atrial oxygen saturation (SPO2) with/without non-invasive oxygen therapy was significantly higher in statin group (P=0.001, P=0.002, respectively). However, other primary and secondary outcomes was similar in both groups.Conclusion: Statin use was associated with higher percentage of SP02, but there were no significant differences in other outcomes.
